SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors eagerly await earnings results, with community chatter focused on iPhone sales and forward guidance. Some anticipate a positive catalyst for a breakout, while others express concerns about valuation and potential downside, especially given mixed reactions to other big tech earnings this week. The stock's reaction post-earnings will likely set the tone for market sentiment.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following its earnings release, with community members closely watching for sustained gains. Discussions revolve around AWS growth, overall profitability, and whether the stock can maintain its upward momentum or if profit-taking will lead to a reversal, similar to other tech stocks.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending amid mixed reactions to its earnings report, which featured strong revenue growth but missed EPS estimates. The community is debating whether the company's heavy Bitcoin holdings and unrealized gains justify the current stock price, with some anticipating a short squeeze while others point to manipulation and dilution concerns. Analysts remain bullish with high price targets despite recent volatility.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors digest its latest earnings report, which featured better-than-expected revenue and EPS, alongside a rise in daily active users. The community is focused on the company's growth prospects and valuation, with some expressing concerns over user growth and heavy moderation, while others point to potential for long-term gains and a possible short squeeze. Hedge fund activity has also spurred conversation, as institutional investors have been increasing their positions in the company.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as investors react to an analyst upgrade from JP Morgan citing potential in Base monetization and USDC yield opportunities. Community chatter suggests a possible run to $400, while others express skepticism based on past earnings performance, and anticipate volatility ahead of the Q3 report. The stock's recent decoupling from Bitcoin's price action is also being noted.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to community discussion around earnings and a recent offering, with debates focusing on the significance of new deals and the company's growth potential. Bulls emphasize the disruptive nature of GSIT's technology and potential partnerships, while bears express concerns about disappointing results and valuation. Some investors speculate about a possible buyout or strategic investment from larger players in the semiconductor industry.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

RKT is trending as investors discuss the potential impact of AI integration and the recent earnings report. Community members are focused on Q4 expenses, the Redfin/Mr. Cooper merger, and future earnings potential amid fluctuating interest rates. Bullish sentiment is building around the company's long-term growth prospects in the mortgage industry.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest recent earnings and pipeline developments, with discussions focused on revenue guidance and the potential of their next-generation inhibitor. Community sentiment appears mixed, with some expressing confidence in management's vision and others concerned about market undervaluation and the ongoing CMS legal battle. Bullish investors are hoping for a breakout driven by strong execution and potential M&A activity.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

DXCM is trending amid mixed sentiment following earnings and news of a leadership transition. While some investors see a buying opportunity due to growth in key markets and a raised full-year revenue outlook, others are concerned about margin pressures, competition, and product quality, particularly with the G7 sensor; the community is actively debating the stock's near-term trajectory.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Blockchain Inc

Riot Blockchain is trending following earnings, with discussions centered around the company's focus on data centers and potential in AI. Community members are reacting to the results, debating whether the stock will continue to climb, while some anticipate news related to HPC progress. The performance of RIOT is also being compared to other miners like $CLSK and $MARA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Schrdinger to Announce Third Quarter 2025 Financial Results on November 5

Schrdinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast...

Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength?

Schrodinger (SDGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrdinger, Inc. (Nasdaq: SDGR) today reported that on October 13, 2025, the company granted restricted stock units (RSUs) with respect to 14,888 shares of the companys common stock to 10 newly hired...

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35.&nbsp;The firm said recent stumbles in Schrodinger’s homegrown drug programs, along with persistent headwinds across biotech and pharma, have dimmed its outlook.<a href="https://stocktwits.com/symbol/SDGR">Shares of Schrodinger</a> fell 2% to $19.45 on Thursday, marking its lowest close in four months, before edging up 0.2% to $19.5 in after-hours trading.The downgrade by the brokerage firm came just after Schrodinger disclosed that it will&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/schrodinger-discontinues-clinical-program-after-two-patient-deaths/chsR0RyRdOb">discontinue the development of SGR-2921</a>, an early-stage CDC7 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.Chief Medical Officer Margaret Dugan said patient safety was the company’s top priority, noting that the drug’s potential as a combination therapy would be challenging to pursue under the circumstances. “While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” she said.Citi said its earlier bullish stance had hinged on three early-stage Phase 1 assets that could validate Schrodinger’s drug discovery platform and attract biopharma partners.&nbsp;The brokerage firm noted that updates so far have “fallen short,” fueling concerns about the future of the company’s internal drug portfolio.SGR-2921 was&nbsp;designed to block CDC7 kinase, a protein overexpressed in many cancers and involved in DNA replication and cell cycle progression.&nbsp;Preclinical data had suggested the drug could work in combination with standard-of-care agents, but Schrodinger said the safety risks outweighed the potential benefits.On Stocktwits, retail sentiment for Schrodinger was ‘bearish’ amid ‘extremely high’ message volume.One user questioned the timing of Schrodinger’s disclosure, noting that the company reported Q2 earnings just eight days ago, and&nbsp;wondered if both patient deaths occurred since then or if the information had been withheld.&nbsp;<stembedurl>https://stocktwits.com/scott52/message/625133866</stembedurl>Another user speculated that there was “more to the news” than disclosed, pointing to the stock’s quick price recovery as a sign that “something fishy” might be going on.<stembedurl>https://stocktwits.com/Buckanator/message/625153259</stembedurl>Schrodinger’s stock has risen 0.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Schrodinger logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.

Equity

Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.The decision was made in light of two treatment-related deaths in the early-stage study, the company said. <a href="https://stocktwits.com/symbol/SDGR">Schrödinger</a> opined that developing the drug as a combination therapy would be difficult to pursue in light of the two deaths despite evidence of activity as a monotherapy.Margaret Dugan, chief medical officer at Schrödinger, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Announces-Discontinuation-of-SGR-2921-Program/default.aspx">said</a>, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”On Stocktwits, retail sentiment around SDGR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. The stock is trading 4% lower in the pre-market session on Thursday.Dugan said the company had hoped to advance the investigational drug for acute myeloid leukemia, a rapidly progressing cancer of the blood and bone marrow, provided there are limited therapies available for the disease. The early-stage study was also supported by preclinical data, which suggested that SGR-2921 could ultimately be used in combination with standard-of-care agents, the company said.SGR-2921 is a CDC7 inhibitor, meaning it is a drug that blocks the activity of the CDC7 kinase, a protein involved in DNA replication and cell cycle progression. CDC7 is often overexpressed in cancer cells, and its inhibition can lead to cell cycle arrest and programmed cell death of these cancer cells.SDGR stock is up by 3% this year and by over 4% in the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-as-investors-await-wholesale-inflation-data/chsRirXRdOG">Dow Futures Edge Lower As Wall Street Watches Out For PPI Report: BLSH, COHR, CSCO Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Schrödinger Discontinues Clinical Program After Two Patient Deaths

SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of +28.92% and +5.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and -1.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?

VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$20.46
Prev Close	$21.15
Open	$20.86
Dividend Yield	0.00%
50-Day Moving Average	$19.96
Beta	1.66
Avg. Volume	1.04M
PE Ratio	-8.52

52-Week High	$28.47
52-Week Low	$16.60
Market Capitalization	$1.56B
EPS (Annual)	-$2.58
Price to Book	4.54
Revenue Per Employee	$232,928.17
Enterprise Value/EBITDA	N/A

SDGR
Schrodinger Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SDGR News

SDGRSchrodinger Inc